Ondansetron - PharmaKB

Ondansetron

Ondansetron (ondansetron) is a small molecule pharmaceutical. Ondansetron was first approved as Zofran on 1991-01-04. It is used to treat alcoholism in the USA.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
chemically-induced disorders	D064419
mental disorders	D001523

Trade Name

FDA

EMA

Ondansetron (discontinued: Ondansetron, Zofran, Zuplenz)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Ondansetron hydrochloride

Tradename	Company	Number	Date	Products
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER	GSK	N-020403 DISCN	1995-01-31	1 products, RLD
ZOFRAN	Sandoz	N-020007 DISCN	1991-01-04	1 products, RLD
ZOFRAN PRESERVATIVE FREE	Sandoz	N-020007 DISCN	1993-12-10	1 products, RLD
ZOFRAN	Sandoz	N-020103 DISCN	1992-12-31	3 products, RLD
ZOFRAN	Sandoz	N-020605 DISCN	1997-01-24	1 products, RLD

Hide discontinued

Ondansetron

Tradename	Company	Number	Date	Products
ZUPLENZ	Aquestive Therapeutics	N-022524 DISCN	2010-07-02	2 products, RLD
ZOFRAN ODT	Sandoz	N-020781 DISCN	1999-01-27	2 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
mko melt dose pack	unapproved drug other	2019-03-04
ondansetron	ANDA	2024-10-31
ondansetron hcl	ANDA	2023-02-08
ondansetron hydrochloride	ANDA	2024-09-25
ondansetron ondansetron hydrochloride	ANDA	2024-05-30
sumansetron	unapproved drug other	2023-01-11
zofran	ANDA	2021-10-01

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
alcoholism	EFO_0003829	D000437	F10.1

Agency Specific

FDA

EMA

No data

Patent Expiration

Patent	Expires	Flag
Ondansetron, Zuplenz, Aquestive
9095577	2030-07-13	DP
8580830	2029-11-23	DP

ATC Codes

A: Alimentary tract and metabolism drugs

— A04: Antiemetics and antinauseants

— A04A: Antiemetics and antinauseants

— A04AA: Serotonin (5ht3) antagonists

— A04AA01: Ondansetron

HCPCS

Code	Description
J2405	Injection, ondansetron hydrochloride, per 1 mg
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
S0119	Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code)

Clinical

Clinical Trials

563 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Vomiting	D014839	HP_0002013	R11.1	17	41	59	54	59	226
Nausea	D009325	HP_0002018	R11.0	14	35	38	43	43	170
Postoperative nausea and vomiting	D020250	EFO_0004888	—	5	15	12	34	38	102
Postoperative pain	D010149	—	G89.18	1	2	1	11	27	41
Neoplasms	D009369	—	C80	4	4	8	3	6	25
Breast neoplasms	D001943	EFO_0003869	C50	—	6	5	3	6	19
Anesthesia	D000758	—	—	—	—	4	3	10	17
Hypotension	D007022	EFO_0005251	I95	1	1	5	4	6	16
Gastroenteritis	D005759	EFO_1001463	K52.9	1	1	7	4	4	16
Alcoholism	D000437	EFO_0003829	F10.1	1	9	4	1	1	15

Show 92 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	3	6	1	—	3	11
Leukemia	D007938	—	C95	2	4	1	—	1	6
Myelodysplastic syndromes	D009190	—	D46	2	4	1	—	1	6
Preleukemia	D011289	—	—	2	4	1	—	1	6
Multiple myeloma	D009101	—	C90.0	2	2	2	—	1	6
Schizophrenia	D012559	EFO_0000692	F20	2	1	2	—	1	6
Myeloid leukemia acute	D015470	—	C92.0	—	3	1	—	—	4
Myeloproliferative disorders	D009196	—	D47.1	1	2	1	—	1	4
Laparoscopy	D010535	—	—	—	—	2	—	2	4
Agnosia	D000377	HP_0030222	F88	—	1	2	—	2	4

Show 46 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Non-hodgkin lymphoma	D008228	—	C85.9	2	4	—	—	1	7
Pancreatic neoplasms	D010190	EFO_0003860	C25	2	2	—	—	1	5
Cocaine-related disorders	D019970	—	F14	—	3	—	—	2	5
Glioma	D005910	EFO_0000520	—	1	4	—	—	—	4
Myeloid leukemia	D007951	—	C92	1	4	—	—	—	4
Bcr-abl positive chronic myelogenous leukemia	D015464	EFO_0000340	—	1	3	—	—	—	3
Hodgkin disease	D006689	—	C81	2	2	—	—	—	3
Melanoma	D008545	—	—	—	3	—	—	—	3
Head and neck neoplasms	D006258	—	—	—	2	—	—	—	2
Sarcoma	D012509	—	—	—	2	—	—	—	2

Show 85 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	17	—	—	—	2	19
Malnutrition	D044342	EFO_0008572	E40-E46	4	—	—	—	1	5
Traumatic brain injuries	D000070642	—	S06	2	—	—	—	2	4
Brain injuries	D001930	—	S06.9	2	—	—	—	2	4
Brain concussion	D001924	—	S06.0	1	—	—	—	2	3
Disease	D004194	EFO_0000408	R69	3	—	—	—	—	3
Covid-19	D000086382	—	—	1	—	—	—	—	1
Post-concussion syndrome	D038223	EFO_1001827	F07.81	1	—	—	—	—	1
Fasting	D005215	EFO_0002756	—	1	—	—	—	—	1
Dyspnea	D004417	HP_0002094	R06.0	1	—	—	—	—	1

Show 4 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Inguinal hernia	D006552	HP_0000023	K40	—	—	—	—	3	3
Male breast neoplasms	D018567	—	—	—	—	—	—	3	3
Conduction anesthesia	D000765	—	—	—	—	—	—	3	3
Coronary artery disease	D003324	—	I25.1	—	—	—	—	2	2
Cardiac surgical procedures	D006348	—	—	—	—	—	—	2	2
Arthritis	D001168	HP_0001369	M05-M14	—	—	—	—	2	2
Hernia	D006547	HP_0100790	K40-K46	—	—	—	—	2	2
Substance withdrawal syndrome	D013375	EFO_0005800	—	—	—	—	—	2	2
Acute pain	D059787	—	R52	—	—	—	—	2	2
Genetic polymorphism	D011110	—	—	—	—	—	—	1	1

Show 58 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Ondansetron
INN	ondansetron
Description	Ondansetron is a member of carbazoles.
Classification	Small molecule
Drug class	serotonin 5-HT3 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O